UCB (OTCMKTS:UCBJY) Lowered to Hold Rating by Barclays

Barclays lowered shares of UCB (OTCMKTS:UCBJY) from a strong-buy rating to a hold rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the company. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, UCB presently has an average rating of “Moderate Buy”.

UCB Trading Down 5.4%

UCBJY stock opened at $150.09 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The stock’s fifty day simple moving average is $145.71 and its two-hundred day simple moving average is $147.35. UCB has a 1-year low of $89.00 and a 1-year high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.